$1.17
+0.10 (+9.35%)
Open$1.12
Previous Close$1.07
Day High$1.18
Day Low$1.11
52W High$8.81
52W Low$0.92
Volume—
Avg Volume261.5K
Market Cap21.95M
P/E Ratio—
EPS$-7.35
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+882.9% upside
Current
$1.17
$1.17
Target
$11.50
$11.50
$7.99
$11.50 avg
$12.09
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 26.36M | 987.4K | 951.3K |
| Net Income | -2,688,556,470 | -74,062 | -66,038 |
| Profit Margin | -374.3% | -7.5% | -6.9% |
| EBITDA | -2,605,617,516 | -123,235 | -109,691 |
| Free Cash Flow | — | -44,936 | -40,091 |
| Rev Growth | — | +23.6% | +13.9% |
| Debt/Equity | 0.01 | 1.06 | 0.89 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |